Organization (Industry)
Argos Therapeutics (United States)
ClinicalTrials.gov lists Argos Therapeutics (United States) as lead sponsor of 10 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Argos Therapeutics (United States): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (8)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Carcinoma, Renal Cell | 7 |
| Kidney Neoplasms | 7 |
| HIV Infections | 3 |
| Acquired Immunodeficiency Syndrome | 2 |
| HIV Seropositivity | 1 |
Showing 5 of 8 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2014 | 2 |
| 2013 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2009 | 1 |
| 2008 | 2 |
| 2007 | 1 |
| 2006 | 2 |
| 2004 | 1 |
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| SUNITINIB | 1 |
Journals published in (34)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of virology | 5 |
| Nature | 4 |
| Journal of immunology (Baltimore, Md. : 1950) | 3 |
| Nature medicine | 3 |
| PloS one | 3 |
Showing 5 of 34 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 41 | 0 | 2019-01-22 |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| McGill University Health Centre | Co sponsors trial with | 1 |
Latest dated events (54)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2019-01-22 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-07-17 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-06-26 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-05-15 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2018-01-30 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 54 events.
Biomarker capability evidence (56)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial sponsor | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CD4 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 56 evidence rows.
On Scientist.com
Argos Therapeutics (United States) is listed as a research supplier in the Scientist.com network.
Service areas
DENDRITIC CELLS: THE IMMUNE SYSTEM´S MASTER SWITCH
Dendritic cells are the master switch that can turn the immune system on or off. Dendritic cells capture, process and identify antigens, or foreign bodies, and alert the body’s immune response, activating antibodies and T cells to destroy the invaders. Without the active engagement of dendritic cells, the immune system is like a huge army, without a general to lead the defense.
- Website
- www.argostherapeutics.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sponsor delivery record, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Argos Therapeutics on Scientist.com
For prices, more details, or to contact Argos Therapeutics, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.